# Therapy for Progressive and/or Refractory Hematologic Malignancies

> **NCT02223312** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Kiromic BioPharma Inc.**

## Conditions studied

- Cancer
- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** TAPA-pulsed DC vaccine

## Key facts

- **NCT ID:** NCT02223312
- **Lead sponsor:** Kiromic BioPharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-28
- **Primary completion:** 2018-10-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to discontinue study.
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223312, "Therapy for Progressive and/or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02223312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*